Literature DB >> 21130607

Confronting multidrug-resistant Acinetobacter baumannii: a review.

Ioannis K Neonakis1, Demetrios A Spandidos, Efthimia Petinaki.   

Abstract

Multidrug-resistant Acinetobacter baumannii (MDR-AB) infections are difficult to treat owing to the extremely limited armamentarium. The present review reports all available treatment options against MDR-AB, including single molecules, combination schemes, and alternative modes of antimicrobial administration. Additionally, a group of recently reported peptides with anti-MDR-AB activity is described.
Copyright © 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21130607     DOI： 10.1016/j.ijantimicag.2010.10.014

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


  40 in total

1.  Genotyping and molecular characterization of clinical Acinetobacter baumannii isolates from a single hospital in Southwestern Iran.

Authors:  Ahmad Farajzadeh Sheikh; Mohammad Savari; Effat Abbasi Montazeri; Saeed Khoshnood
Journal:  Pathog Glob Health       Date:  2020-06-19       Impact factor: 2.894

2.  A 4-year surveillance of antimicrobial resistance patterns of Acinetobacter baumanni in a university-affiliated hospital in China.

Authors:  Ting Xu; Wenying Xia; Guodong Rong; Shiyang Pan; Peijun Huang; Bing Gu
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

3.  Detection of class 1 integron in Acinetobacter baumannii isolates collected from nine hospitals in Turkey.

Authors:  Ayşegül Çopur Çıçek; Azer Özad Düzgün; Ayşegül Saral; Tuba Kayman; Zeynep Çızmecı; Pervin Özlem Balcı; Tuba Dal; Mehmet Fırat; İsmail Tosun; Yasemin Ay Alıtntop; Ahmet Çalışkan; Yelda Yazıcı; Cemal Sandallı
Journal:  Asian Pac J Trop Biomed       Date:  2013-09

4.  In-silico modeling of a novel OXA-51 from β-lactam-resistant Acinetobacter baumannii and its interaction with various antibiotics.

Authors:  Vishvanath Tiwari; Isha Nagpal; Naidu Subbarao; Rajeswari R Moganty
Journal:  J Mol Model       Date:  2012-01-22       Impact factor: 1.810

5.  Modification of Salmonella Lipopolysaccharides Prevents the Outer Membrane Penetration of Novobiocin.

Authors:  Thatyane M Nobre; Michael W Martynowycz; Konstantin Andreev; Ivan Kuzmenko; Hiroshi Nikaido; David Gidalevitz
Journal:  Biophys J       Date:  2015-12-15       Impact factor: 4.033

Review 6.  Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

Authors:  Darren Wong; Travis B Nielsen; Robert A Bonomo; Paul Pantapalangkoor; Brian Luna; Brad Spellberg
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

7.  OXA-23 Is a Prevalent Mechanism Contributing to Sulbactam Resistance in Diverse Acinetobacter baumannii Clinical Strains.

Authors:  Yunxing Yang; Qingye Xu; Tingting Li; Ying Fu; Yue Shi; Peng Lan; Dongdong Zhao; Qiong Chen; Zhihui Zhou; Yan Jiang; Anton Y Peleg; Yunsong Yu
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

8.  Geographical patterns in antimicrobial resistance of acinetobacter in clinical isolates.

Authors:  Naz Perween; Sonal Sehgal; S Krishna Prakash
Journal:  J Clin Diagn Res       Date:  2014-04-15

9.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

10.  Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3.

Authors:  Krisztina M Papp-Wallace; Baui Senkfor; Julian Gatta; Weirui Chai; Magdalena A Taracila; Veerabahu Shanmugasundaram; Seungil Han; Richard P Zaniewski; Brian M Lacey; Andrew P Tomaras; Marion J Skalweit; Michael E Harris; Louis B Rice; John D Buynak; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.